Bill > HB648

This bill requires health insurance providers, including individual and group plans, health service corporations, and health maintenance organizations (HMOs), to cover medically appropriate and necessary glucose monitoring devices and their associated supplies for individuals diagnosed with Type 2 diabetes or gestational diabetes. This coverage extends to both traditional blood glucose monitors and continuous glucose monitoring systems (CGMS), which are defined as devices that continuously measure glucose levels. The bill also mandates coverage for necessary supplies such as sensors, transmitters, receivers, lancets, and test strips. Importantly, coverage for these devices and supplies will not be subject to deductibles, and insurers cannot require insulin utilization, specific insulin administration frequencies, or a minimum frequency of blood glucose testing as a condition for coverage. Furthermore, insurers must include at least two types of each device in their preferred provider networks or formularies, and an endocrinology referral or prior authorization will not be required. To continue receiving coverage, individuals must participate in follow-up care with their healthcare provider at least every six months for the first 18 months of monitoring, and then at least annually thereafter. The bill also includes a provision to cap the out-of-pocket cost for a 30-day supply of prescription insulin drugs at $30, without being subject to a deductible.

Business and Industry

https://gc.nh.gov/bill_Status/billinfo.aspx?id=126&inflect=2